An update on bone imaging and markers in chronic kidney disease

References

• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S1–130.
   Google Scholar
• Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223–3232.
   PubMed Web of Science ®Google Scholar
• Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396–399.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70(7):1358–1366.
   PubMed Web of Science ®Google Scholar
• Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86(4):810–818.
   PubMed Web of Science ®Google Scholar
• Lin JC, Liang WM. Mortality and complications after hip fracture among elderly patients undergoing hemodialysis. BMC Nephrol. 2015;16:100.
   PubMed Web of Science ®Google Scholar
• Beaubrun AC, Kilpatrick RD, Freburger JK, et al. Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. J Am Soc Nephrol. 2013;24(9):1461–1469.
   PubMed Web of Science ®Google Scholar
• Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000;11(5):460–466.
   PubMed Web of Science ®Google Scholar
• Nikitovic M, Wodchis WP, Krahn MD, et al. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int. 2013;24(2):659–669.
   PubMed Web of Science ®Google Scholar
• Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22(1):124–136.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
   PubMed Web of Science ®Google Scholar
• Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011;22(10):1913–1922.
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lau KK, Strauss BJ, et al. Relationship between vascular calcification, arterial stiffness and bone mineral density in a cross-sectional study of prevalent Australian haemodialysis patients. Nephrology. 2009;14(1):105–112.
   PubMed Web of Science ®Google Scholar
• Chen NX, O’Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62(5):1724–1731.
   PubMed Web of Science ®Google Scholar
• Moe SM, O’Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61(2):638–647.
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Ogata H, Hatamura I, et al. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant. 2006;21(4):911–916.
   PubMed Web of Science ®Google Scholar
• Jimbo R, Kawakami-Mori F, Mu S, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of klotho deficiency. Kidney Int. 2014;85(5):1103–1111.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Amizuka N, Oda K, et al. Histological and elemental analyses of impaired bone mineralization in klotho-deficient mice. J Anat. 2008;212(3):275–285.
   PubMed Web of Science ®Google Scholar
• Murali SK, Roschger P, Zeitz U, et al. FGF23 regulates bone mineralization in a 1,25(OH)2 D3 and klotho-independent manner. J Bone Miner Res. 2016;31(1):129–142.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, D’Haese P, Sclerostin BV. DKK1: new players in renal bone and vascular disease. Kidney Int. 2015;88(2):235–240.
   PubMed Web of Science ®Google Scholar
• Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990;38(2):193–211.
   PubMed Web of Science ®Google Scholar
• Cannata-Andia JB. Hypokinetic azotemic osteodystrophy. Kidney Int. 1998;54(3):1000–1016.
   PubMed Web of Science ®Google Scholar
• Wheater G, Elshahaly M, Tuck SP, et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013;11:201.
   PubMed Web of Science ®Google Scholar
• Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem. 1994;55(3):287–299.
   PubMed Web of Science ®Google Scholar
• Pereira RC, Juppner H, Azucena-Serrano CE, et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45(6):1161–1168.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883–19887.
   PubMed Web of Science ®Google Scholar
• Sabbagh Y, Graciolli FG, O’Brien S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27(8):1757–1772.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26(6):1368–1376.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67(4):559–566.
   PubMed Web of Science ®Google Scholar
• Gal-Moscovici A, Sprague SM. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S170–174.
   PubMed Web of Science ®Google Scholar
• Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant. 1996;11(5):813–819.
   PubMed Web of Science ®Google Scholar
• Coen G, Ballanti P, Bonucci E, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91(1):103–111.
   PubMed Web of Science ®Google Scholar
• Jamal SA, West SL, Nickolas TL. The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int. 2014;25(1):71–76.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Porter DS, Monier-Faugere MC, et al. Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol. 2012;23(3):525–532.
   PubMed Web of Science ®Google Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192.
   PubMed Web of Science ®Google Scholar
• Issack PS, Helfet DL, Lane JM. Role of Wnt signaling in bone remodeling and repair. HSS J. 2008;4(1):66–70.
   PubMedGoogle Scholar
• Day TF, Guo X, Garrett-Beal L, et al. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8(5):739–750.
   PubMed Web of Science ®Google Scholar
• Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216–224.
   PubMed Web of Science ®Google Scholar
• Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248–255.
   PubMed Web of Science ®Google Scholar
• Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6(4):877–882.
   PubMed Web of Science ®Google Scholar
• Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):819–823.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Siriopol D, Saglam M, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014;99(10):E1854–1861.
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577–4583.
   PubMed Web of Science ®Google Scholar
• Ishimura E, Okuno S, Ichii M, et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab. 2014;99(11):4315–4320.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Davenport DL, Cantor T, et al. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol. 2014;9(7):1254–1262.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol. 2013;14:219.
   PubMed Web of Science ®Google Scholar
• Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res. 2015;30(3):499–509.
   PubMed Web of Science ®Google Scholar
• Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278(39):37419–37426.
   PubMed Web of Science ®Google Scholar
• Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637–1647.
   PubMed Web of Science ®Google Scholar
• Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18(10):2683–2688.
   PubMed Web of Science ®Google Scholar
• Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–568.
   PubMed Web of Science ®Google Scholar
• Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5–achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22(4):1171–1176.
   PubMed Web of Science ®Google Scholar
• Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656–1663.
   PubMed Web of Science ®Google Scholar
• Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–692.
   PubMed Web of Science ®Google Scholar
• Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500–6505.
   PubMed Web of Science ®Google Scholar
• Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38(11):1248–1250.
   PubMed Web of Science ®Google Scholar
• Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23(6):939–948.
   PubMed Web of Science ®Google Scholar
• Liao HW, Hung PH, Hsiao CY, et al. Relationship between fibroblast growth factor 23 and biochemical and bone histomorphometric alterations in a chronic kidney disease rat model undergoing parathyroidectomy. Plos One. 2015;10(7):e0133278.
   Web of Science ®Google Scholar
• Kanaan N, Claes K, Devogelaer JP, et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol. 2010;5(10):1887–1892.
   PubMed Web of Science ®Google Scholar
• Urena Torres P, Friedlander G, de Vernejoul MC, et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008;73(1):102–107.
   PubMed Web of Science ®Google Scholar
• Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;280(4):1015–1020.
   PubMed Web of Science ®Google Scholar
• Tan SJ, Smith ER, Hewitson TD, et al. The importance of klotho in phosphate metabolism and kidney disease. Nephrology. 2014;19(8):439–449.
   PubMed Web of Science ®Google Scholar
• Dermaku-Sopjani M, Sopjani M, Saxena A, et al. Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem. 2011;28(2):251–258.
   PubMed Web of Science ®Google Scholar
• Ikushima M, Rakugi H, Ishikawa K, et al. Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun. 2006;339(3):827–832.
   PubMed Web of Science ®Google Scholar
• Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol. 2013;9(11):650–660.
   PubMed Web of Science ®Google Scholar
• Kawano K, Ogata N, Chiano M, et al. Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res. 2002;17(10):1744–1751.
   PubMed Web of Science ®Google Scholar
• Faugere MC, Arnala IO, Ritz E, et al. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med. 1986;107(6):481–487.
   PubMed Web of Science ®Google Scholar
• Smith AJ, Faugere MC, Abreo K, et al. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol. 1986;6(4):275–283.
   PubMed Web of Science ®Google Scholar
• Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res. 1995;10(1):149–156.
   PubMed Web of Science ®Google Scholar
• Cohen-Solal ME, Sebert JL, Boudailliez B, et al. Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?. Bone. 1992;13(1):1–5.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Chen H, et al. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail. 2014;36(8):1244–1252.
   PubMed Web of Science ®Google Scholar
• Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure–an evolving disorder. Kidney Int. 1993;43(2):436–442.
   PubMed Web of Science ®Google Scholar
• de Oliveira RA, Barreto FC, Mendes M, et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2015;87(5):1039–1045.
   PubMed Web of Science ®Google Scholar
• Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int. 1995;47(5):1434–1442.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44(5):1071–1077.
   PubMed Web of Science ®Google Scholar
• Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994;9(5):517–523.
   PubMed Web of Science ®Google Scholar
• Inaba M, Nagasue K, Okuno S, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis. 2002;39(6):1261–1269.
   PubMed Web of Science ®Google Scholar
• Coen G, Mantella D, Manni M, et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005;68(4):1840–1848.
   PubMed Web of Science ®Google Scholar
• Ambrus C, Almasi C, Berta K, et al. Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol. 2011;43(2):475–482.
   PubMed Web of Science ®Google Scholar
• Jean G, Terrat JC, Vanel T, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008;23(11):3670–3676.
   PubMed Web of Science ®Google Scholar
• Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab. 1990;70(4):930–938.
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Moyses RM, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 2006;69(10):1852–1857.
   PubMed Web of Science ®Google Scholar
• Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28(5):1029–1040.
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996;97(11):2534–2540.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Brancaccio D, Gallieni M, et al. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol. 2005;18(1):5–8.
   PubMed Web of Science ®Google Scholar
• Cejka D, Patsch JM, Weber M, et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011;6(9):2264–2271.
   PubMed Web of Science ®Google Scholar
• Mares J, Ohlidalova K, Opatrna S, et al. Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients. J Bone Miner Metab. 2009;27(2):217–223.
   PubMed Web of Science ®Google Scholar
• Jorgetti V, Dos Reis LM, Ott SM. Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD. Kidney Int. 2014;85(6):1283–1289.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int. 1984;25(4):677–682.
   PubMed Web of Science ®Google Scholar
• Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int. 2012;23(4):1191–1198.
   PubMed Web of Science ®Google Scholar
• Jeong JU, Lee HK, Kim YJ, et al. Nutritional markers, not markers of bone turnover, are related predictors of bone mineral density in chronic peritoneal dialysis patients. Clin Nephrol. 2010;74(5):336–342.
   PubMed Web of Science ®Google Scholar
• Panuccio V, Enia G, Tripepi R, et al. Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. BMC Nephrol. 2012;13:134.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Saraiva M, Behets G, et al. Evaluation of bone remodeling in hemodialysis patients: serum biochemistry, circulating cytokines and bone histomorphometry. J Nephrol. 2009;22(6):783–793.
   PubMed Web of Science ®Google Scholar
• Sugiya N, Nakashima A, Takasugi N, et al. Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life. Osteoporos Int. 2011;22(5):1573–1579.
   PubMed Web of Science ®Google Scholar
• Mundy GR, Shapiro JL, Bandelin JG, et al. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest. 1976;58(3):529–534.
   PubMed Web of Science ®Google Scholar
• Haris A, Szabo A, Lanyi E, et al. Acute and long-term effects of corticosteroid therapy on bone metabolism in patients with kidney diseases. Clin Nephrol. 2012;78(1):17–23.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57(3):445–449.
   PubMed Web of Science ®Google Scholar
• Taal MW, Masud T, Green D, et al. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999;14(8):1922–1928.
   PubMed Web of Science ®Google Scholar
• Kirkpantur A, Altun B, Arici M, et al. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clin Pract. 2009;63(2):261–268.
   PubMed Web of Science ®Google Scholar
• Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544–550.
   PubMed Web of Science ®Google Scholar
• Rojas E, Carlini RG, Clesca P, et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int. 2003;63(5):1915–1923.
   PubMed Web of Science ®Google Scholar
• Lemann J Jr., Litzow JR, Lennon EJ. The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest. 1966;45(10):1608–1614.
   PubMed Web of Science ®Google Scholar
• Moore C, Yee J, Malluche H, et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(9):1484–1493.
   PubMed Web of Science ®Google Scholar
• Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20(8):1653–1661.
   PubMed Web of Science ®Google Scholar
• Neves KR, Graciolli FG, Dos Reis LM, et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 2004;66(6):2237–2244.
   PubMed Web of Science ®Google Scholar
• Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996;28(4):596–602.
   PubMed Web of Science ®Google Scholar
• Schober HC, Han ZH, Foldes AJ, et al. Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol. 1998;9(7):1225–1233.
   PubMed Web of Science ®Google Scholar
• Weijenberg MP, Feskens EJ, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscler Thromb Vasc Biol. 1996;16(4):499–503.
   PubMed Web of Science ®Google Scholar
• Scientific Advisory Council of the Osteoporosis Society of C, Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1–34.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Watts NB, McClung MR, et al. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab. 2004;89(8):3651–3655.
   PubMed Web of Science ®Google Scholar
• Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis risk assessment. JAMA. 2001;286(22):2815–2822.
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.. JAMA. 1999;282(14):1344–1352.
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Miller MA, Chin J, Miller SC, et al. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 1998;23(3):257–266.
   PubMed Web of Science ®Google Scholar
• Lobao R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol. 2004;62(6):432–439.
   PubMed Web of Science ®Google Scholar
• Haas M, Leko-Mohr Z, Roschger P, et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis. 2002;39(3):580–586.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis. 2007;49(5):674–681.
   PubMed Web of Science ®Google Scholar
• Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant. 2012;27(1):345–351.
   PubMed Web of Science ®Google Scholar
• Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7(7):1130–1136.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2015;87(3):502–528.
   PubMed Web of Science ®Google Scholar
• Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014;29(3):518–530.
   PubMed Web of Science ®Google Scholar
• Brunerova L, Ronova P, Veresova J, et al. Osteoporosis and impaired trabecular bone score in hemodialysis patients. Kidney Blood Press Res. 2016;41(3):345–354.
   PubMed Web of Science ®Google Scholar
• Blomquist GA, Davenport DL, Mawad HW, et al. Diagnosis of low bone mass in CKD-5D patients. Clin Nephrol. 2016;85(2):77–83.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Porter DS, Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nat Rev Nephrol. 2013;9(11):671–680.
   PubMed Web of Science ®Google Scholar
• Engelke K, Adams JE, Armbrecht G, et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions. J Clin Densitom. 2008;11(1):123–162.
   PubMed Web of Science ®Google Scholar
• Australian Radiation Protection and Nuclear Safety Agency. Code of Practice for Radiation Protection in the Medical Applications of Ionizing Radiation. Barton, Australia, 2008.
   Google Scholar
• Leonard MB. A structural approach to skeletal fragility in chronic kidney disease. Semin Nephrol. 2009;29(2):133–143.
   PubMed Web of Science ®Google Scholar
• Lima EM, Goodman WG, Kuizon BD, et al. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrology. 2003;18(6):554–559.
   PubMed Web of Science ®Google Scholar
• Russo CR, Taccetti G, Caneva P, et al. Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Osteoporos Int. 1998;8(5):443–448.
   PubMed Web of Science ®Google Scholar
• Terpstra AM, Kalkwarf HJ, Shults J, et al. Bone density and cortical structure after pediatric renal transplantation. J Am Soc Nephrol. 2012;23(4):715–726.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Gilbert J, Gordon C, et al. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006;21(4):543–548.
   PubMed Web of Science ®Google Scholar
• Negri AL, Barone R, Lombas C, et al. Evaluation of cortical bone by peripheral quantitative computed tomography in continuous ambulatory peritoneal dialysis patients. Hemodial Int. 2006;10(4):351–355.
   PubMedGoogle Scholar
• Saland JM, Goode ML, Haas DL, et al. The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. Am J Transplant. 2001;1(3):243–250.
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–2261.
   PubMed Web of Science ®Google Scholar
• Ferretti JL, Capozza RF, Zanchetta JR. Mechanical validation of a tomographic (pQCT) index for noninvasive estimation of rat femur bending strength. Bone. 1996;18(2):97–102.
   PubMed Web of Science ®Google Scholar
• Sheu Y, Zmuda JM, Boudreau RM, et al. Bone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2011;26(1):63–71.
   PubMed Web of Science ®Google Scholar
• Lala D, Cheung AM, Gordon C, et al. Comparison of cortical bone measurements between pQCT and HR-pQCT. J Clin Densitom. 2012;15(3):275–281.
   PubMed Web of Science ®Google Scholar
• Lala D, Cheung AM, Lynch CL, et al. Measuring apparent trabecular structure with pQCT: a comparison with HR-pQCT. J Clin Densitom. 2014;17(1):47–53.
   PubMed Web of Science ®Google Scholar
• Bacchetta J, Boutroy S, Vilayphiou N, et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res. 2010;25(4):849–857.
   PubMed Web of Science ®Google Scholar
• Negri AL, Del Valle EE, Zanchetta MB, et al. Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients. Osteoporos Int. 2012;23(10):2543–2550.
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Stein EM, Dworakowski E, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8):1811–1820.
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21(8):1371–1380.
   PubMed Web of Science ®Google Scholar
• Jamal S, Cheung AM, West S, et al. Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int. 2012;23(12):2805–2813.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Masterson R, Holt SG, et al. Emerging role of high resolution imaging in the detection of renal osteodystrophy. Nephrology. 2016;21:801–811.
   PubMedGoogle Scholar
• Krug R, Burghardt AJ, Majumdar S, et al. High-resolution imaging techniques for the assessment of osteoporosis. Radiol Clin North Am. 2010;48(3):601–621.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Wagner J, Nelson JB, et al. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy. J Bone Miner Res. 2013;28(2):325–332.
   PubMed Web of Science ®Google Scholar
• Wehrli FW, Rajapakse CS, Magland JF, et al. Mechanical implications of estrogen supplementation in early postmenopausal women. J Bone Miner Res. 2010;25(6):1406–1414.
   PubMed Web of Science ®Google Scholar
• Folkesson J, Goldenstein J, Carballido-Gamio J, et al. Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. Bone. 2011;48(3):611–621.
   PubMed Web of Science ®Google Scholar
• D’Elia G, Caracchini G, Cavalli L, et al. Bone fragility and imaging techniques. Clin Cases Miner Bone Metab. 2009;6(3):234–246.
   PubMedGoogle Scholar
• Wehrli FW, Leonard MB, Saha PK, et al. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging. 2004;20(1):83–89.
   PubMed Web of Science ®Google Scholar
• Rajapakse CS, Leonard MB, Bhagat YA, et al. Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation. Radiology. 2012;262(3):912–920.
   PubMed Web of Science ®Google Scholar
• Damilakis J, Adams JE, Guglielmi G, et al. Radiation exposure in X-ray-based imaging techniques used in osteoporosis. Eur Radiol. 2010;20(11):2707–2714.
   PubMed Web of Science ®Google Scholar
• Henzell S, Dhaliwal S, Pontifex R, et al. Precision error of fan-beam dual X-ray absorptiometry scans at the spine, hip, and forearm. J Clin Densitom. 2000;3(4):359–364.
   PubMed Web of Science ®Google Scholar
• Lehmann G, Stein G, Huller M, et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68(3):1206–1214.
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73(6):771–777.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Souberbielle JC, Lafage-Proust MH, et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant. 2014;29(5):997–1004.
   PubMed Web of Science ®Google Scholar
• Gardham C, Stevens PE, Delaney MP, et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol. 2010;5(7):1261–1267.
   PubMed Web of Science ®Google Scholar
• Yamada S, Inaba M, Kurajoh M, et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf). 2008;69(2):189–196.
   PubMed Web of Science ®Google Scholar
• Sardiwal S, Gardham C, Coleman AE, et al. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int. 2012;82(1):100–105.
   PubMed Web of Science ®Google Scholar
• Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41(5):997–1007.
   PubMed Web of Science ®Google Scholar
• Miwa N, Nitta K, Kimata N, et al. An evaluation of 1-84 PTH measurement in relation to bone alkaline phosphatase and bone Gla protein in hemodialysis patients. Nephron Clin Pract. 2003;94(2):c29–32.
   PubMedGoogle Scholar
• Sardiwal S, Magnusson P, Goldsmith DJ, et al. Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis. 2013;62(4):810–822.
   PubMed Web of Science ®Google Scholar
• Haarhaus M, Monier-Faugere MC, Magnusson P, et al. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study. Am J Kidney Dis. 2015;66(1):99–105.
   PubMed Web of Science ®Google Scholar
• Fletcher S, Jones RG, Rayner HC, et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron. 1997;75(4):412–419.
   PubMed Web of Science ®Google Scholar
• Cavalier E, Lukas P, Carlisi A, et al. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta. 2013;425:117–118.
   PubMed Web of Science ®Google Scholar
• Alvarez L, Torregrosa JV, Peris P, et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J Bone Miner Metab. 2004;22(3):254–259.
   PubMed Web of Science ®Google Scholar
• Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26(4):97–122.
   PubMedGoogle Scholar
• Chu P, Chao TY, Lin YF, et al. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis. 2003;41(5):1052–1059.
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Simpson SA, Yarnoff BO, et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis. 2015;65(3):403–411.
   PubMed Web of Science ®Google Scholar